200 related articles for article (PubMed ID: 26403329)
21. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
22. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
23. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
Rossi ED; Bizzarro T; Martini M; Capodimonti S; Fadda G; Larocca LM; Schmitt F
Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
[TBL] [Abstract][Full Text] [Related]
24. A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma.
Kim YH; Choi SE; Yoon SO; Hong SW
Hum Pathol; 2014 Jul; 45(7):1483-8. PubMed ID: 24745617
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
26. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.
Zerilli M; Zito G; Martorana A; Pitrone M; Cabibi D; Cappello F; Giordano C; Rodolico V
Mod Pathol; 2010 Aug; 23(8):1052-60. PubMed ID: 20473281
[TBL] [Abstract][Full Text] [Related]
27. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
[TBL] [Abstract][Full Text] [Related]
28. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
Takano T; Ito Y; Hirokawa M; Yoshida H; Miyauchi A
Br J Cancer; 2007 May; 96(10):1549-53. PubMed ID: 17453004
[TBL] [Abstract][Full Text] [Related]
29. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
30. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
32. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
[TBL] [Abstract][Full Text] [Related]
33. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
Liu D; Liu Z; Condouris S; Xing M
J Clin Endocrinol Metab; 2007 Jun; 92(6):2264-71. PubMed ID: 17374713
[TBL] [Abstract][Full Text] [Related]
34. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
[TBL] [Abstract][Full Text] [Related]
35. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
[TBL] [Abstract][Full Text] [Related]
36. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
37. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
38. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
Takahashi K; Eguchi H; Arihiro K; Ito R; Koyama K; Soda M; Cologne J; Hayashi Y; Nakata Y; Nakachi K; Hamatani K
Mol Carcinog; 2007 Mar; 46(3):242-8. PubMed ID: 17186541
[TBL] [Abstract][Full Text] [Related]
39. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
40. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]